OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Pharmacological Sciences is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Subscription and Copyright Information	644
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	424
Subscription and Copyright Information	252
Subscription and Copyright Information	178
Subscription and Copyright Information	163
Advisory Board and Contents	157
Structural asymmetry in FGF23 signaling	153
Subscription and Copyright Information	142
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	140
Targeting of Potassium Channels in Cardiac Arrhythmias	131
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	131
Structural pharmacology and mechanisms of GLP-1R signaling	120
Muscarinic receptors: from clinic to bench to clinic	106
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	104
Shearing of surface mucin saps tumor cell strength	104
Direct in vivo CAR T cell engineering	92
Peptides as a therapeutic strategy against Klebsiella pneumoniae	90
Compstatins: the dawn of clinical C3-targeted complement inhibition	88
Targeting complement in neurodegeneration: challenges, risks, and strategies	88
Therapeutic inhibition of ferroptosis in neurodegenerative disease	80
Advisory Board and Contents	79
Advisory Board and Contents	78
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	78
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	77
Phenotypic approaches for CNS drugs	71

Emerging strategies for beta cell transplantation to treat diabetes	68
A smart hospital-driven approach to precision pharmacovigilance	65
Ribosome-directed cancer therapies: the tip of the iceberg?	62
HSV-1 as a gene delivery platform for cancer gene therapy	61
Advisory Board and Contents	60
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	60
A deep dive into degrader-induced protein-protein interfaces	59
A perspective on psychedelic teratogenicity: the utility of zebrafish models	57
Engineering ACE2 decoy receptors to combat viral escapability	56
Advisory Board and Contents	56
siRNA drug Leqvio (inclisiran) to lower cholesterol	56
Leveraging human microbiomes for disease prediction and treatment	56
Genetically engineered loaded extracellular vesicles for drug delivery	56
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	56
Mentoring future science leaders to thrive	54
Could dexmedetomidine be repurposed as a glymphatic enhancer?	52
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19	51
The structure, function, and pharmacology of MRGPRs	50
Subscription and Copyright Information	50
Close to a year in TIPS’ saddle – I am optimistic	50
Thriving as members of under-represented groups in pharmacology-related careers	49
Emerging approaches to induce immune tolerance to therapeutic proteins	49
Lipoxygenases in chronic liver diseases: current insights and future perspectives	48